Machida S - Search Results

1

Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer.

Machida S, Ohwada M, Fujiwara H, Konno R, Takano M, Kita T, Kikuchi Y, Komiyama S, Mikami M, Suzuki M. Machida S, et al. Oncology. 2003;65(2):102-7. doi: 10.1159/000072333. Oncology. 2003. PMID: 12931014 Clinical Trial.

2

Establishment of a new cell line (TAYA) of clear cell adenocarcinoma of the ovary and its radiosensitivity.

Saga Y, Suzuki M, Machida S, Ohwada M, Sato I. Saga Y, et al. Among authors: machida s. Oncology. 2002;62(2):180-4. doi: 10.1159/000048265. Oncology. 2002. PMID: 11914605

3

A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer.

Takei Y, Suzuki M, Ohwada M, Saga Y, Kohno T, Machida S, Sato I. Takei Y, et al. Among authors: machida s. Oncol Rep. 2003 Jul-Aug;10(4):951-5. Oncol Rep. 2003. PMID: 12792751 Clinical Trial.

4

Abnormal fragile histidine triad expression in advanced cervical cancer and evaluation of its utility as a prognostic factor.

Machida S, Ohwada M, Saga Y, Suzuki M. Machida S, et al. Oncology. 2003;65(1):89-93. doi: 10.1159/000071209. Oncology. 2003. PMID: 12837987

5

Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies.

Shimada M, Fujiwara H, Sato S, Oishi T, Itamochi H, Machida S, Takei Y, Harada T, Suzuki M, Kigawa J. Shimada M, et al. Among authors: machida s. Cancer Chemother Pharmacol. 2012 Jul;70(1):33-8. doi: 10.1007/s00280-012-1885-z. Epub 2012 May 18. Cancer Chemother Pharmacol. 2012. PMID: 22610355 Clinical Trial.

6

Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma.

Machida S, Sato T, Fujiwara H, Saga Y, Takei Y, Taneichi A, Nonaka H, Suzuki M. Machida S, et al. Oncol Lett. 2012 Nov;4(5):1017-1022. doi: 10.3892/ol.2012.853. Epub 2012 Aug 6. Oncol Lett. 2012. PMID: 23162643 Free PMC article.

7

Radiation therapy for chemotherapy-resistant recurrent epithelial ovarian cancer.

Machida S, Takei Y, Yoshida C, Takahashi Y, Koyanagi T, Sato N, Taneichi A, Saga Y, Fujiwara H, Suzuki M. Machida S, et al. Oncology. 2014;86(4):232-8. doi: 10.1159/000357269. Epub 2014 May 13. Oncology. 2014. PMID: 24853194

8

[Abnormal fragile histidine triad and cervical cancer].

Machida S, Saga Y, Ohwada M, Suzuki M. Machida S, et al. Nihon Rinsho. 2004 Oct;62 Suppl 10:69-72. Nihon Rinsho. 2004. PMID: 15535208 Review. Japanese. No abstract available.

9

Cetuximab inhibits growth, peritoneal dissemination, and lymph node and lung metastasis of endometrial cancer, and prolongs host survival.

Takahashi K, Saga Y, Mizukami H, Takei Y, Machida S, Fujiwara H, Ozawa K, Suzuki M. Takahashi K, et al. Among authors: machida s. Int J Oncol. 2009 Oct;35(4):725-9. doi: 10.3892/ijo_00000385. Int J Oncol. 2009. PMID: 19724908

10

Indoleamine 2,3-dioxygenase promotes peritoneal dissemination of ovarian cancer through inhibition of natural killercell function and angiogenesis promotion.

Nonaka H, Saga Y, Fujiwara H, Akimoto H, Yamada A, Kagawa S, Takei Y, Machida S, Takikawa O, Suzuki M. Nonaka H, et al. Among authors: machida s. Int J Oncol. 2011 Jan;38(1):113-20. Int J Oncol. 2011. PMID: 21109932

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

561 results

Search Page

Filters